drugset / Trial / NCT05249972
A Phase III Study in Subjects With Mild to Moderate Psoriasis.
RandomizedParallel-groupTriple-blindTreatment
Summary
A randomized, assessor blind, parallel group, three arms, active and placebo controlled study with objective to demonstrate therapeutic non-inferiority of AKP02 cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO) versus Enstilar cutaneous foam (calcipotriol 50 μg/g + betamethasone 0.5 mg/g) in subjects with mild to moderate plaque psoriasis.
Timeline
- Start
- 2022-01-24
- Primary completion
- 2022-08-11
- Completion
- 2022-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Betamethasone | Other / unclassified | 0.5 unknown | Topical |
| Subject | Calcipotriol | Small molecule | 50 unknown | Topical |